Susan Weiss recalls some of her 40 years of coronavirus research on coronaviruses, including mouse hepatitis virus, MERS-CoV, and now SARS-CoV-2.

Daniel Griffin updates the clinical situation with COVID-19 patients, followed by analysis of the remedesivir clinical trial results, and answers listener questions.

Jeff Shaman returns to TWiV to explain why more SARS-CoV-2 testing and contact tracing is needed to stop the pandemic, and provide insights on immunity and reinfection from seasonal CoVs, the problems with antibody tests, and what to expect in the coming months.

Daniel Griffin provides his weekly update on the COVID-19 clinical situation, followed by our discussion of tests of an inactivated vaccine, results of serological surveys, an inhibitor of the cell protease needed for virus entry, and answers to listener questions.

Ralph Baric, Mark Heise and Nat Moorman discuss their non-profit initiative READDI, Rapidly Emerging Antiviral Drug Discovery Initiative, to start making drugs now for the next pandemic virus.

Kostya Chumakov discusses the hypothesis that oral poliovirus vaccine can provide non-specific protection against many other viruses, and might prevent infection with SARS-CoV-2.

Daniel Griffin provides his weekly update on the COVID-19 clinical situation, followed by results of seroprevalence studies, analysis of CpG dinucleotide frequencies in the SARS-CoV-2 genome, and answers to listener questions.

Stanley Perlman joins TWiV to discuss immune responses to coronaviruses, including seasonal CoV, MERS, SARS, and SARS-CoV-2, including prospects for a vaccine.

Coronavirus expert Christian Drosten joins Vincent to provide a view from Germany on COVID-19 and SARS-CoV-2.

Daniel Griffin joins TWiV to update on the clinical situation, then we discuss a 382 nucleotide deletion in the SARS-CoV-2 genome, a scenario for emergence of the virus from a bat, followed by answers to listener email.